Epidermal Growth Factor is Effective in the Treatment of Diabetic Foot Ulcers: Meta-Analysis and Systematic Review

Thien Quoc Bui, Quoc Van Phu Bui, Dávid Németh, Péter Hegyi, Zsolt Szakács, Zoltán Rumbus, Barbara Tóth, Gabriella Emri, Andrea Párniczky, Patricia Sarlós and Orsolya Varga
Additional contact information
Thien Quoc Bui: Department of Preventive Medicine, Faculty of Medicine, University of Debrecen, 4028 Debrecen, Hungary
Quoc Van Phu Bui: Department of Internal Medicine, Faculty of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh city 70000, Vietnam
Dávid Németh: Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary
Péter Hegyi: Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary
Zsolt Szakács: Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary
Zoltán Rumbus: Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary
Barbara Tóth: Department of Pharmacognosy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary
Gabriella Emri: Department of Dermatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
Andrea Párniczky: Heim Pál National Institute of Pediatrics, 1089 Budapest, Hungary
Patricia Sarlós: Division of Gastroenterology, First Department of Medicine, University of Pécs, Medical School, 7624 Pécs, Hungary
Orsolya Varga: Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, 4028 Debrecen, Hungary

IJERPH, 2019, vol. 16, issue 14, 1-13

Abstract: Diabetic foot ulcers (DFUs) are one the common complications of diabetes mellitus. Many trials were performed to evaluate the effect of recombinant human epidermal growth factor (rhEGF) in healing DFUs. This meta-analysis was performed to synthesize the evidence of rhEGF treatment in DFUs in comparison to placebo. Databases included for the search were PubMed, EMBASE, the Cochrane Library, Web of Science, EBSCOhost, ScienceDirect, and Scopus (up to January 2019). The outcome of interest was the complete healing rate of DFUs. We performed random effects meta-analysis stratified by the types of administration route (intralesional injection and topical apply) by calculating the odds ratios (OR) and 95% confidence interval (95% CI). A total of six studies involving 530 patients were eligible for analysis. The combined OR (intralesional injection and topical apply) was 4.005 (95% CI: (2.248; 7.135), p < 0.001). The ORs for intralesional injection and topical application were 3.599 (95% CI: (1.213; 10.677), p = 0.021) and 4.176 (95% CI: (2.112; 8.256), p < 0.001), respectively. Statistical heterogeneity might not be important in overall treatment (I 2 = 15.17, p = 0.317) and both of the subgroups (I 2 : 24.56, p = 0.25 and I 2 : 33.26, p = 0.213, respectively). Our results support the use of rhEGF in the treatment of DFUs.

Keywords: recombinant human epidermal growth factor; placebo; diabetic mellitus; diabetic foot ulcer; meta-analysis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/16/14/2584/pdf (application/pdf)
https://www.mdpi.com/1660-4601/16/14/2584/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:16:y:2019:i:14:p:2584-:d:249905

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().